E-DRUG: Independent Drug & Healthcare Newsletter for July 2017
--------------------------------------------------------------------------------
Newsletter, July 2017
If your friends or colleagues would be interested, forward this email and invite them to sign up for the free Newsletter.
N° 184 July 2017
View the table of contents for the current issue
Subscribe to Prescrire International
In Prescrire's Spotlight this month
----------------------------------------
Equine oestrogens + bazedoxifene (Duavive°) and menopause. Inadequately evaluated harms.
FEATURED REVIEW A new product combining equine oestrogens and bazedoxifene (Duavive°, Pfizer) has been authorised in the European Union for menopausal disorders in non-hysterectomised postmenopausal women. Past experience suggests that this new combination should be considered with caution, and avoided until these foreseeable adverse effects have been properly evaluated.
Read more
--------------------------------------------------------------------------------
In the July issue of Prescrire International: The adverse effects of the cytotoxic temsirolimus and the opioid pholcodine.
FREE DOWNLOAD In the Adverse Effects section of this issue, the cardiac risks of the cytotoxic immunosuppressant temsirolimus, used in metastatic renal cell carcinoma and mantle cell lymphoma,
and the harms caused by the opioid pholcodine, still present in many cough suppressants.
Read more
--------------------------------------------------------------------------------
Pertuzumab: of variable benefit depending on the type of breast cancer.
In some patients with metastatic breast cancer, pertuzumab in combination with trastuzumab + docetaxel is proven to extend life, but at the cost of increased cardiac adverse effects. There is no evidence that this drug is beneficial as a neoadjuvant treatment when the breast cancer has not metastasised.
Read more
--------------------------------------------------------------------------------
Pregnancy and Graves' disease: opt for treatments posing the lowest maternal and fetal risks.
Treatment of pregnant women with Graves' disease (hyperthyroidism) is problematic since all drug therapies carry significant risks. Some synthetic antithyroid drugs are the treatment of choice.
Read more
--------------------------------------------------------------------------------
Who are we? A non-profit continuing education organisation, committed to better patient care
Prescrire and Prescrire International provide independent information, by and for healthcare professionals. Since 1981, Prescrire has provided healthcare professionals - and via them, patients - with the clear, comprehensive and reliable information they need about drugs and therapeutic and diagnostic strategies.
Read more
Prescrire International <international@prescrire.org>